37 related articles for article (PubMed ID: 38554788)
21. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.
Popovics P; Frigo DE; Schally AV; Rick FG
Expert Opin Ther Targets; 2015 May; 19(5):617-32. PubMed ID: 25600663
[TBL] [Abstract][Full Text] [Related]
22. Ferroptosis: A New Promising Target for Lung Cancer Therapy.
Xiong R; He R; Liu B; Jiang W; Wang B; Li N; Geng Q
Oxid Med Cell Longev; 2021; 2021():8457521. PubMed ID: 34616505
[TBL] [Abstract][Full Text] [Related]
23. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract][Full Text] [Related]
24. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
Liu S; Alabi BR; Yin Q; Stoyanova T
Semin Cancer Biol; 2022 Nov; 86(Pt 3):57-68. PubMed ID: 35597438
[TBL] [Abstract][Full Text] [Related]
26. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.
Wozney JL; Antonarakis ES
Cancer Metastasis Rev; 2014 Sep; 33(2-3):581-94. PubMed ID: 24402967
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Models of Neuroendocrine Prostate Cancer.
Cacciatore A; Albino D; Catapano CV; Carbone GM
Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
[TBL] [Abstract][Full Text] [Related]
28. Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.
Shui X; Xu R; Zhang C; Meng H; Zhao J; Shi C
Lab Invest; 2022 Apr; 102(4):332-340. PubMed ID: 34937865
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
30. AMPK's double-faced role in advanced stages of prostate cancer.
Gharibpoor F; Kamali Zonouzi S; Razi S; Rezaei N
Clin Transl Oncol; 2022 Nov; 24(11):2064-2073. PubMed ID: 35781781
[TBL] [Abstract][Full Text] [Related]
31. [Neuroendocrine prostate cancer].
Kretschmer A; Wittekind C; Stief CG; Gratzke C
Urologe A; 2015 Dec; 54(12):1779-83. PubMed ID: 26582381
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.
Morgan TM; Koreckij TD; Corey E
Curr Cancer Drug Targets; 2009 Mar; 9(2):237-49. PubMed ID: 19275762
[TBL] [Abstract][Full Text] [Related]
33. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer.
Wang Y; Wu N; Li J; Liang J; Zhou D; Cao Q; Li X; Jiang N
Pharmacol Res; 2024 May; 203():107162. PubMed ID: 38554788
[TBL] [Abstract][Full Text] [Related]
34. Molecular events in neuroendocrine prostate cancer development.
Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic modulations and lineage plasticity in advanced prostate cancer.
Ge R; Wang Z; Montironi R; Jiang Z; Cheng M; Santoni M; Huang K; Massari F; Lu X; Cimadamore A; Lopez-Beltran A; Cheng L
Ann Oncol; 2020 Apr; 31(4):470-479. PubMed ID: 32139297
[TBL] [Abstract][Full Text] [Related]
36. Autophagy-Dependent Ferroptosis as a Therapeutic Target in Cancer.
Liu L; Li L; Li M; Luo Z
ChemMedChem; 2021 Oct; 16(19):2942-2950. PubMed ID: 34110079
[TBL] [Abstract][Full Text] [Related]
37. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.
Santoni M; Conti A; Burattini L; Berardi R; Scarpelli M; Cheng L; Lopez-Beltran A; Cascinu S; Montironi R
Biochim Biophys Acta; 2014 Dec; 1846(2):630-7. PubMed ID: 25450825
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]